Return to Gastrointestinal Stromal Tumors Specialty Channel

Gastrointestinal Stromal Tumors Newswatch

Results of a phase 1 trial indicate ripretinib may be a beneficial treatment option for patients with refractory advanced GIST.
Prolonged adjuvant imatinib for high-risk GIST led to a superior OS over shorter-term imatinib treatment, according to a trial comparing 3- and 1-year regimens.
Using first-line multi-kinase inhibitors (MKIs) aside from imatinib did not lead to early resistance or decreased efficacy of second-line therapy for metastatic GIST.
A retrospective analysis suggests that the clinical features and treatment approaches for multiple GISTs may differ from single GISTs, presenting a gap in the treatment landscape.
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results…
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
OS improved for patients with advanced GIST treated with ripretinib, according to follow-up study findings presented at the 2020 Virtual ESMO Annual Meeting.
Stay in the know.
OncNet Newsletter